Compare WMK & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | ZYME |
|---|---|---|
| Founded | 1912 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1994 | 2022 |
| Metric | WMK | ZYME |
|---|---|---|
| Price | $72.39 | $26.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 123.4K | ★ 643.1K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $4,714,573,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.15 | ★ N/A |
| Revenue Growth | 0.01 | ★ 38.87 |
| 52 Week Low | $59.99 | $15.79 |
| 52 Week High | $83.74 | $31.34 |
| Indicator | WMK | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 45.11 |
| Support Level | $67.85 | $22.10 |
| Resistance Level | $72.51 | $27.33 |
| Average True Range (ATR) | 1.57 | 1.20 |
| MACD | 0.40 | -0.49 |
| Stochastic Oscillator | 66.58 | 4.34 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.